The four-fold increase in cellular MTA is similar to the increase in MTA observed in MTAP−/− cancer cell lines when compared to MTAP+/+ isogenic lines16,17, indicating that in this mouse model, MTDIA therapy results in a physiologic mimic of an MTAP genetic deletion. The gene discussed is MTAP; the disease is cancer.